Literature DB >> 29581542

Detailed genomic characterization identifies high heterogeneity and histotype-specific genomic profiles in adrenocortical carcinomas.

Simona Vatrano1, Marco Volante2, Eleonora Duregon1, Jessica Giorcelli1, Stefania Izzo1, Ida Rapa1, Arianna Votta1, Antonina Germano1, Giorgio Scagliotti1, Alfredo Berruti3, Massimo Terzolo4, And Mauro Papotti5.   

Abstract

Molecular characterization of adrenocortical carcinoma has been recently established, but the correlation between molecular profiles and clinical and pathological characteristics is still poorly defined with no data available about genetic heterogeneity along disease progression. In this scenario, a detailed molecular profile was correlated with clinical and pathological characteristics in adrenocortical carcinoma patients to identify potentially novel biomarkers. Targeted next-generation sequencing and copy number variation analyses for 18 most frequently altered genes in adrenocortical carcinoma were assessed on 62 adult cases (including 10 with matched primary and metastatic/recurrence samples) and results correlated with major clinical and pathological characteristics of tumors. A total of 433 somatic deleterious genetic alterations (328 gene mutations and 105 copy number variations) were identified in 57/62 cases, five resulted wild type for all genes tested. TERT, CDK4, ZNRF3,and RB1 were altered in more than 30% of cases. Among histological variants genotypes were significantly different. Lowest mutation burden was found in the oncocytic type (p = 0.006), whereas the highest with a prevalence of RB1 (p = 0.001) and CDK4 (p = 0.002) was found in the conventional and myxoid ones, respectively. None of the 10 cases with matched samples showed a stable genotype along tumor progression, although allelic frequencies or percentages of altered nuclei at fluorescence in situ hybridization were in most cases similar among different tumor samples for genes that were stable along tumor progression. Among individual genes, an altered p53/Rb1 pathway was the strongest adverse molecular signature, being associated with high Ki-67 index, high tumor stage, aggressive disease status, and shorter disease-free survival. The genomic signature in adrenocortical carcinoma is changing along tumor progression and is associated with specific clinical and pathological features, including histological variant and prognosis.

Entities:  

Mesh:

Year:  2018        PMID: 29581542     DOI: 10.1038/s41379-018-0042-6

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  10 in total

1.  Metastatic Adrenal Cortical Carcinoma Responding to Octreotide: A Case Report.

Authors:  Xiang Wang; Na Zhou; Yu Xiao; Wenjia Zhu; Chunmei Bai; Lin Zhao
Journal:  Oncologist       Date:  2019-05-09

2.  Intratumor heterogeneity of prognostic DNA-based molecular markers in adrenocortical carcinoma.

Authors:  Anne Jouinot; Juliane Lippert; Martin Fassnacht; Bruno de La Villeon; Amandine Septier; Mario Neou; Karine Perlemoine; Silke Appenzeller; Mathilde Sibony; Sébastien Gaujoux; Bertrand Dousset; Rossella Libe; Lionel Groussin; Cristina L Ronchi; Guillaume Assié; Jérôme Bertherat
Journal:  Endocr Connect       Date:  2020-07       Impact factor: 3.335

Review 3.  Adrenocortical carcinoma - towards genomics guided clinical care.

Authors:  Joakim Crona; Felix Beuschlein
Journal:  Nat Rev Endocrinol       Date:  2019-09       Impact factor: 43.330

Review 4.  Adrenocortical Carcinoma: Updates of Clinical and Pathological Features after Renewed World Health Organisation Classification and Pathology Staging.

Authors:  Alfred King-Yin Lam
Journal:  Biomedicines       Date:  2021-02-10

5.  SIRT1 is involved in adrenocortical cancer growth and motility.

Authors:  Adele Chimento; Arianna De Luca; Marta Claudia Nocito; Sara Sculco; Paola Avena; Davide La Padula; Lucia Zavaglia; Rosa Sirianni; Ivan Casaburi; Vincenzo Pezzi
Journal:  J Cell Mol Med       Date:  2021-03-02       Impact factor: 5.310

Review 6.  Estrogen Receptors-Mediated Apoptosis in Hormone-Dependent Cancers.

Authors:  Adele Chimento; Arianna De Luca; Paola Avena; Francesca De Amicis; Ivan Casaburi; Rosa Sirianni; Vincenzo Pezzi
Journal:  Int J Mol Sci       Date:  2022-01-22       Impact factor: 5.923

Review 7.  Endocrine and Neuroendocrine Tumors Special Issue-Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?

Authors:  Camilo Jimenez; Gustavo Armaiz-Pena; Patricia L M Dahia; Yang Lu; Rodrigo A Toledo; Jeena Varghese; Mouhammed Amir Habra
Journal:  Cancers (Basel)       Date:  2022-01-18       Impact factor: 6.639

8.  Estrogen Related Receptor Alpha (ERRα) a Bridge between Metabolism and Adrenocortical Cancer Progression.

Authors:  Paola Avena; Arianna De Luca; Adele Chimento; Marta Claudia Nocito; Sara Sculco; Davide La Padula; Lucia Zavaglia; Matteo Giulietti; Constanze Hantel; Rosa Sirianni; Ivan Casaburi; Vincenzo Pezzi
Journal:  Cancers (Basel)       Date:  2022-08-11       Impact factor: 6.575

Review 9.  Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma.

Authors:  Chiara Fiorentini; Salvatore Grisanti; Deborah Cosentini; Andrea Abate; Elisa Rossini; Alfredo Berruti; Sandra Sigala
Journal:  J Oncol       Date:  2019-04-01       Impact factor: 4.375

Review 10.  Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance.

Authors:  Marta Araujo-Castro; Eider Pascual-Corrales; Javier Molina-Cerrillo; Teresa Alonso-Gordoa
Journal:  Biomedicines       Date:  2021-03-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.